Commit Biologics
Developing a novel platform technology that utilizes the complement system, a crucial component of the innate immune system, to potentially create new treatments for various cancers and autoimmune diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
* | €5.5m Valuation: €80.0m | Seed | |
| Total Funding | 000k | ||
| DKK | 2022 | 2023 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
Commit Biologics, a biotech spin-out from Aarhus University founded in 2021, focuses on developing groundbreaking immunotherapy treatments for cancer. The company leverages a unique mechanism of action that activates the complement system, an efficient immune mechanism, to target and destroy tumor cells. This novel approach has the potential to redefine cancer treatment by stimulating an adaptive immune response and efficiently clearing tumor cells. Commit Biologics primarily serves the oncology market, targeting healthcare providers and research institutions looking for advanced cancer treatment solutions. The business model revolves around research and development, with revenue generated through partnerships, grants, and potential future sales of their proprietary immunotherapy treatments. The company's innovative technology and promising results have attracted a group of investors who believe in the potential of their work.
Keywords: immunotherapy, cancer treatment, complement system, tumor cells, adaptive immune response, biotech, oncology, research, development, innovative technology.